RSS

Bavencio (avelumab)

A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC more

News

The FDA has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. more

News